Free press releases distribution network?

Agency / Source: Bioquark, Inc.

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products - The common mosquito, while being responsible for up to a million human deaths each year, may paradoxically also hold biochemical secrets to cure diseases that effect hundreds of millions of people around the globe - Bioquark.com
Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products

 

PRTODAY - Newswire & PRZOOM/ - Philadelphia, PA, United States, 01/10/2019 - The common mosquito, while being responsible for up to a million human deaths each year, may paradoxically also hold biochemical secrets to cure diseases that effect hundreds of millions of people around the globe - Bioquark.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Bioquark, Inc., an innovative life sciences company focused biotherapeutic development for human regeneration and disease reversion, and Ectocrine Technologies, LLC, a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, of have announced a collaboration to focus on developing novel bio-products for human health and wellness.

"We are very excited about this collaboration with Ectocrine Technologies," said Ira S. Pastor, CEO, Bioquark Inc. "The synergy of our approaches in studying evolutionarily perfected arrays of metabolites from the natural world, can lead to the development of novel therapeutics for a range of chronic diseases responsible for human degeneration and suffering. And nature’s ectocrine systems (the “Ectocrinome”) represents a completely un-tapped reservoir."

Nature’s ectocrine systems (or “Ectocrinome”, in similar model to the Microbiome), form an interlaced network across species, providing a range of beneficial bio-active effects. The saliva of mosquitos, as example, has been shown to contain novel neuro-peptides, anti-inflammatory molecules, anti-coagulants, pain killers, as well as a range of vasodilatory and immune-modulatory molecules. However, most of this knowledge has been completely obscured due to the extensive popular press focus on the mosquito being no more than a disease carrying pest.

Mosquito eradication programs, while offering a solution to the million deaths each year from mosquito born disease, ignore the critical immunopathological role that these creatures have played over hundreds of millions of years as they propagated their beneficial biochemical signals in invertebrates, fish, amphibians, reptiles, birds, mammals, and humans. While hygiene represents one of the most successful health / life extending interventions in history, many epidemiological studies show that, paradoxically, it may render humans at risk for the development of a range of chronic non-communicable diseases (NCDs), such as inflammatory bowel disease, multiple sclerosis, type I diabetes, asthma, and allergies. Furthermore, these pathological process might play a broad role in the pathogenesis of other NCDs associated with chronic inflammation such as atherosclerosis, type 2 diabetes, cancer, and neurodegenerative disorders.

"We look forward to working closely with Bioquark Inc. on this exciting initiative," said Dr. J. Santiago Mejia MD, CSO of Ectocrine Technologies, LLC. "The epidemiological evidence of low incidences of auto-immune diseases, inflammatory disorders, allergies, developmental diseases and certain cancers, in regions of high endemicity for arthropod-borne diseases, may interestingly point us towards previously ignored answers to combat these major causes of human degeneration and disease."

“We are not advocating for the suspension of the vector control programs used to eradicate malaria and other arthropod-borne diseases. Our concern is that these methods fail to discriminate infected from non-infected mosquitos, and as a result, residents of intervened areas are deprived of the potential health benefits derived from exposure to the salivary molecules delivered through the bite of healthy mosquitos,” said Mejia.

About Bioquark, Inc.

Bioquark, Inc. (bioquark.com) is an innovative life sciences company focused on the development of novel bio-products for human regeneration, disease reversion and rejuvenation, in relation to aging and age related pathologies.

About Ectocrine Technologies

Ectocrine Technologies, LLC is a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, as an essential source of molecules for human well-being and development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Bioquark, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
|
Contact: Ira S. Pastor - Bioquark.com 
267-507-6155 pastor[.]bioquark.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health ProductsAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From Bioquark, Inc. / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

STEMCELL Technologies Launches mTeSR™ Plus - A Next-Generation Culture System for Human ES and iPS Cell Maintenance
Sartorius Stedim Biotech Launches Services for Characterization of New Biological Entities (NBE)
Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products
Sartorius to Demonstrate Special Data Analysis At Night of Knowledge Event Series
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)
Cell Therapy Market to Grow Beyond Oncology As Big Pharma Expands Investments Finds Frost & Sullivan
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims
FDA Approves Genentech’s Tecentriq in Combination with Avastin and Chemotherapy
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib
Ipsen and 3BP Announce First Patient Dosed in Phase I/II study for First-in-Class Radionuclide (IPN01087)

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  Limelon Advertising, Co.

Visit  BizJobs.com

Visit  RightITnow, Inc.





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)